Literature DB >> 20027190

The role of SRC-3 in human breast cancer.

Ondrej Gojis1, Bharath Rudraraju, Mihir Gudi, Katy Hogben, Sami Sousha, R Charles Coombes, Charles R Coombes, Susan Cleator, Carlo Palmieri.   

Abstract

Members of the nuclear receptor superfamily are ligand-regulated transcription factors involved in the control of a broad range of normal physiological and disease processes. The estrogen receptor alpha (ERalpha) is a member of the steriod receptor family, which is part of the nuclear receptor superfamily. ERalpha it is important for many biological processes and plays a key role in the pathogenesis of breast cancer. Gene regulation by ERalpha requires the recruitment of a multitude of transcriptional co-regulators to the promoters of estrogen-responsive genes. There is evidence in support of the involvement of these co-regulators in breast cancer progression. We review the role of steroid receptor co-activator-3 (SRC-3), which is frequently amplified in breast cancer, and its role in breast cancer risk, outcome and response to endocrine therapy in patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20027190     DOI: 10.1038/nrclinonc.2009.219

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  63 in total

Review 1.  The role of coactivators in steroid hormone action.

Authors:  C Bevan; M Parker
Journal:  Exp Cell Res       Date:  1999-12-15       Impact factor: 3.905

2.  Altered expression of estrogen receptor coregulators during human breast tumorigenesis.

Authors:  L C Murphy; S L Simon; A Parkes; E Leygue; H Dotzlaw; L Snell; S Troup; A Adeyinka; P H Watson
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

3.  The transcriptional coactivators p300 and CBP are histone acetyltransferases.

Authors:  V V Ogryzko; R L Schiltz; V Russanova; B H Howard; Y Nakatani
Journal:  Cell       Date:  1996-11-29       Impact factor: 41.582

4.  Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

Authors:  Raimund Jakesz; Walter Jonat; Michael Gnant; Martina Mittlboeck; Richard Greil; Christoph Tausch; Joern Hilfrich; Werner Kwasny; Christian Menzel; Hellmut Samonigg; Michael Seifert; Guenther Gademann; Manfred Kaufmann; Johann Wolfgang
Journal:  Lancet       Date:  2005 Aug 6-12       Impact factor: 79.321

5.  Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.

Authors:  Francesco Boccardo; Alessandra Rubagotti; Matteo Puntoni; Pamela Guglielmini; Domenico Amoroso; Angela Fini; Giuseppe Paladini; Mario Mesiti; Domenico Romeo; Michela Rinaldini; Simona Scali; Mauro Porpiglia; Chiara Benedetto; Nunzio Restuccia; Franco Buzzi; Roberto Franchi; Bruno Massidda; Vito Distante; Dino Amadori; Piero Sismondi
Journal:  J Clin Oncol       Date:  2005-07-11       Impact factor: 44.544

6.  Hybrid selection of transcribed sequences from microdissected DNA: isolation of genes within amplified region at 20q11-q13.2 in breast cancer.

Authors:  X Y Guan; J Xu; S L Anzick; H Zhang; J M Trent; P S Meltzer
Journal:  Cancer Res       Date:  1996-08-01       Impact factor: 12.701

7.  Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer.

Authors:  J Kurebayashi; T Otsuki; H Kunisue; K Tanaka; S Yamamoto; H Sonoo
Journal:  Clin Cancer Res       Date:  2000-02       Impact factor: 12.531

8.  Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Authors:  Raimund Jakesz; Richard Greil; Michael Gnant; Marianne Schmid; Werner Kwasny; Ernst Kubista; Brigitte Mlineritsch; Christoph Tausch; Michael Stierer; Friedrich Hofbauer; Karl Renner; Christian Dadak; Ernst Rücklinger; Hellmut Samonigg
Journal:  J Natl Cancer Inst       Date:  2007-12-11       Impact factor: 13.506

9.  The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function.

Authors:  N L Chamberlain; E D Driver; R L Miesfeld
Journal:  Nucleic Acids Res       Date:  1994-08-11       Impact factor: 16.971

10.  Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.

Authors:  Antoni Hurtado; Kelly A Holmes; Timothy R Geistlinger; Iain R Hutcheson; Robert I Nicholson; Myles Brown; Jie Jiang; William J Howat; Simak Ali; Jason S Carroll
Journal:  Nature       Date:  2008-11-12       Impact factor: 49.962

View more
  26 in total

1.  MIF and autophagy: a novel link beyond "eating".

Authors:  Omar El Bounkari; Jürrgen Bernhagen
Journal:  Cell Res       Date:  2012-05-08       Impact factor: 25.617

2.  A hormonal cue promotes timely follicle cell migration by modulating transcription profiles.

Authors:  Lathiena Manning; Jinal Sheth; Stacey Bridges; Afsoon Saadin; Kamsi Odinammadu; Deborah Andrew; Susan Spencer; Denise Montell; Michelle Starz-Gaiano
Journal:  Mech Dev       Date:  2017-06-10       Impact factor: 1.882

3.  The importance of Src signaling in sarcoma.

Authors:  Quanchi Chen; Zifei Zhou; Liancheng Shan; Hui Zeng; Yingqi Hua; Zhengdong Cai
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

Review 4.  Metabolic Dysregulation Controls Endocrine Therapy-Resistant Cancer Recurrence and Metastasis.

Authors:  Malachi A Blundon; Subhamoy Dasgupta
Journal:  Endocrinology       Date:  2019-08-01       Impact factor: 4.736

Review 5.  Functional analysis of Cullin 3 E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Zhiwei Wang; Brian J North; Kaixiong Tao; Xiangpeng Dai; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-11-08       Impact factor: 10.680

6.  A potential target for liver cancer management, lysophosphatidic acid receptor 6 (LPAR6), is transcriptionally up-regulated by the NCOA3 coactivator.

Authors:  Xuan Zheng; Yinghui Jia; Lei Qiu; Xinyi Zeng; Liangliang Xu; Mingtian Wei; Canhua Huang; Cong Liu; Liangyi Chen; Junhong Han
Journal:  J Biol Chem       Date:  2019-12-30       Impact factor: 5.157

Review 7.  Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.

Authors:  Priscilla A Furth; M Carla Cabrera; Edgar S Díaz-Cruz; Sarah Millman; Rebecca E Nakles
Journal:  Ann N Y Acad Sci       Date:  2011-07       Impact factor: 5.691

8.  Steroid receptor co-activator-3 promotes osteosarcoma progression through up-regulation of FoxM1.

Authors:  Shuo Geng; Xiaoyu Wang; Xiaoyan Xu; Hepeng Zhang; Yan Ma; Yunqi Zhang; Baoxin Li; Zhenggang Bi; Chenglin Yang
Journal:  Tumour Biol       Date:  2013-11-27

9.  The role of AIB1 in breast cancer.

Authors:  Alan K Chang; Huijian Wu
Journal:  Oncol Lett       Date:  2012-07-16       Impact factor: 2.967

10.  Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.

Authors:  Xiunan Li; Yumei Wu; Aihui Liu; Xin Tang
Journal:  Tumour Biol       Date:  2016-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.